Talk:Riociguat
 | This article is rated Start-class on Wikipedia's content assessment scale. It is of interest to the following WikiProjects: |
||||||||||||||||||||
| |||||||||||||||||||||
 | Ideal sources for Wikipedia's health content are defined in the guideline Wikipedia:Identifying reliable sources (medicine) and are typically review articles. Here are links to possibly useful sources of information about Riociguat.
|
Mmol must be an error ?
The article states "concentration between 0.1 and 100 mmol". This can't be right. Especially since the drug is dosed in milligram quantities, and 1 mmol/liter is already 0.44 gram per liter body fluid. 92.109.179.168 (talk) 20:19, 31 July 2016 (UTC)
- The source says µM, nor mM. Thanks for catching this! --ἀνυπόδητος (talk) 18:34, 1 August 2016 (UTC)
Copypaste issues
This issue is a unique one. The Text at this site is "May be freely distributed and Coppied" though they do say they want to be acknolaged as the Author, what is WP policy on this? --MWOAP (talk) 17:57, 19 December 2009 (UTC)
- If by "text", you mean "abstracts from journal articles," then the answer is definitely and absolutely NOT.
- The meaning of the paragraph beginning "Note:" is "Things written by the PubMed staff, like the 'PubMed comprises more than 19 million citations for biomedical articles from MEDLINE and life science journals' text on our main page is fair game, but anything published in a medical journal is copyrighted by the author and/or publisher, not us, and you need to respect their intellectual property."
- The text in question is a simple and direct copyright violation of an abstract from a journal article and should be removed immediately. WhatamIdoing (talk) 02:31, 20 December 2009 (UTC), copied here from WT:PHARM by ἀνυπόδητος (talk) 09:06, 20 December 2009 (UTC)
Citation help for broken link
Anypodetos the reference "Background Riociguat". Bayer HealthCare. Retrieved 15 December 2009 link is dead. Could you help me update this? I found a source that has all of the information that the original press release had.
Ghofrani, Hossein-Ardeschir; D'Armini, Andrea M.; Grimminger, Friedrich; Hoeper, Marius M.; Jansa, Pavel; Kim, Nick H.; Mayer, Eckhard; Simonneau, Gerald; Wilkins, Martin R.; Fritsch, Arno; Neuser, Dieter; Weimann, Gerrit; Wang, Chen (25 July 2013). "Riociguat for the Treatment of Chronic Thromboembolic Pulmonary Hypertension". New England Journal of Medicine. 369 (4): 319–329. doi:10.1056/NEJMoa1209657. ISSN 0028-4793. Retrieved 3 February 2017.
- Thanks for finding this source! I added it to the second occurrence of the old one (since it's about CHEST-1; PATENT-1 doesn't seem to be mentioned). I also removed the third occurrence (covered by the ClinicalTrials reference in the next sentence). I didn't find anything about riogiguat being the first in class (although that's certainly true). --ἀνυπόδητος (talk) 17:55, 3 February 2017 (UTC)